+ Watch VPHM
on My Watchlist
A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.
Nothing much to see here except some correction green thumbing. ViroPharma is getting dragged down along with most other biopharma mid caps despite the impressive growth in Cinryze sales. Vancocin revenues are shrinking to nothing but that was expected once the generic serpent hatched. The share price bottomed at 20 after the bad news broke about generics and then rose over 30 at the height of September's biopharma fever. The stock may well be headed back to 20 if broad market weakness continues, but at some point the winds will shift again.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions